Figure 1
From: Weekly epirubicin in patients with hormone-resistant prostate cancer
Per cent change in UCa/Cr and PSA in responders and non-responders, after 12 treatment cycles. P<0.05 (X2 -test), significantly different between PSA and UCa/Cr in non-responding patients; in parentheses, n=number of patients.
